Guest guest Posted February 26, 2008 Report Posted February 26, 2008 Might the following have an impact on the Supplement Industry? Can the Supplement Industry rally together for certain court-approved protections? Supremes leaning toward pre-emption? <http://www.uptilt.com/c.html?rtr=on & s=69l,xtmb,238i,g384,dj45,65c6,97w5 > Comment <http://www.uptilt.com/c.html?rtr=on & s=69l,xtmb,238i,3lk0,lt86,65c6,97w5 #comment> | Forward to a friend <http://www.uptilt.com/c.html?rtr=on & s=69l,xtmb,238i,6l7a,ienb,65c6,97w5 > Yesterday court-watchers got another sneak peek at which way the Supreme Court might lean when they hear the big drug liability case next term. In hearing arguments over Michigan's law that shields pharma from liability suits unless they commit fraud to get their drug approved, Justices Breyer and Kennedy " expressed broad skepticism " about liability suits against drug makers, Forbes reports. Breyer said--and this is key--that the suits second-guess the FDA's decision to approve the drug. An expert agency is better qualified to make decisions about a drug's safety than is a jury of 12 randomly selected citizens, Breyer said. Of course, that sentiment is just what drugmakers would like to see borne out when the Court takes on the case of Wyeth v. Levine in October. In that case, the court is being asked to determine whether FDA approval pre-empts personal injury lawsuits. Last week, the Supremes decided that for medical devices, a specific type of rigorous FDA approval does shield manufacturers from liability suits <http://www.uptilt.com/c.html?rtr=on & s=69l,xtmb,238i,6f68,hite,65c6,97w5 > . If the wind were ever blowing in drugmakers' favor on this issue, it's now. Before the Bush administration, the FDA argued that lawsuits gave patients additional protection, the New York Times notes. Now, the administration says <http://www.uptilt.com/c.html?rtr=on & s=69l,xtmb,238i,els8,4gwj,65c6,97w5 > lawsuits conflict with the agency's ability to do its job. So, apparently, believes Justice Alito, who asked yesterday whether a state lawsuit should be allowed to proceed even though it might " very seriously interfere with what the FDA is doing. " Ironically, part of the government's argument in this case is that the FDA competently oversees the drug and device markets. An assessment that, after recent expert critique and importation snafus, is certainly open to question <http://www.uptilt.com/c.html?rtr=on & s=69l,xtmb,238i,8y8r,egys,65c6,97w5 > . - read the Forbes article <http://www.uptilt.com/c.html?rtr=on & s=69l,xtmb,238i,lijd,bqvy,65c6,97w5 > - check out the NYT article <http://www.uptilt.com/c.html?rtr=on & s=69l,xtmb,238i,20x1,e7bw,65c6,97w5 > Court Struggles With Pharma Suits By CHRISTOPHER S. RUGABER 02.25.08, 4:44 PM ET WASHINGTON - The Supreme Court on Monday wrestled with a Michigan law that shields pharmaceutical companies from product liability lawsuits, unless they committed fraud to get their drug approved. At issue is whether that fraud exception, which allows lawsuits to proceed, is preempted by federal regulation of pharmaceuticals. , a lawyer for Pfizer Inc. (nyse: PFE <http://finapps.forbes.com/finapps/jsp/finance/compinfo/CIAtAGlance.jsp? tkr=PFE> - news <http://www.forbes.com/markets/company_news.jhtml?ticker=PFE> - people <http://www.forbes.com/peopletracker/results.jhtml?startRow=0 & name= & tick er=PFE> ), told the justices that it should be. " There is a very unique federal interest " in the Food and Drug Administration's regulation of pharmaceuticals, he said. " There is no legitimate state interest here. " The dispute stems from several suits against Warner-Lambert over its diabetes drug Rezulin. Warner-Lambert is now owned by Pfizer. Justices Breyer and Kennedy appeared to side with Pfizer, expressing broad skepticism about product liability suits against pharmaceutical companies. Breyer said they essentially second-guess the FDA's decision to approve the drug. Breyer's remarks are significant because the court has already accepted a case for its next term, which begins in October, that takes on the broader issue of when drug companies can be held liable for products that have been approved by the FDA. That case is Wyeth v. Levine, 06-1249. Other justices, however, were more sympathetic to allowing the suits to proceed. Justice s dismissed concerns raised by the Bush administration that they would prove burdensome to the FDA as " theoretical. " Monday's case is one of several before the court that tests the limits of federal preemption of state regulations in areas such as drugs, medical devices and online tobacco sales. The justices ruled last Wednesday in a case involving Medtronic Inc. (nyse: MDT <http://finapps.forbes.com/finapps/jsp/finance/compinfo/CIAtAGlance.jsp? tkr=MDT> - news <http://www.forbes.com/markets/company_news.jhtml?ticker=MDT> - people <http://www.forbes.com/peopletracker/results.jhtml?startRow=0 & name= & tick er=MDT> ) that federal regulation of advanced medical devices preempts lawsuits in state courts against their manufacturers. The case before the court Monday won't provide as broad a shield against lawsuits as the Medtronic case, because it won't apply to all pharmaceutical suits. Instead, it focuses on a specific issue: whether state courts can consider allegations that a drug company misled the Food and Drug Administration to win approval for a drug. In a 2001 ruling, the justices said that lawsuits alleging " fraud on the FDA " are preempted by federal law, because they interfere with the federal government's regulation of pharmaceuticals. The question in this case is whether that means the exception in Michigan's law is also preempted. The Food and Drug Administration ordered Rezulin off the market in March 2000 after it was linked to nearly 400 deaths and hundreds of cases of liver failure. A group of 27 Michigan plaintiffs, including relatives of six Rezulin patients who died from liver damage, sued Warner-Lambert after the FDA ordered Rezulin off the market in 2000. The drug has been linked to nearly 400 deaths. Zieve, a lawyer for the plaintiffs, argued the Michigan law is different than the one struck down by the court in 2001, because proving fraud on the FDA " is just the first step to litigating " the product liability suit. Claims of fraud against the agency aren't the focus of the case, she said. The court's decision could impact laws in seven other states that shield the pharmaceutical industry from liability, but provide some exceptions in the case of fraud. Chief Justice has recused himself from the case. He owns between $15,001 and $50,000 in Pfizer stock, according to his latest financial disclosure form. The case is Warner-Lambert v. Kent, 06-1498. A decision is expected by July. Copyright 2008 Associated Press. All rights reserved. This material may not be published broadcast, rewritten, or redistributed Kalman PhD, RD, CCRC, FACN Miami Research Associates Director, Nutrition & Applied Clinical Research 6141 Sunset Drive Suite 301 Miami, FL. 33143 Ph: / 598-3125 Fax www.miamiresearch.com <http://www.miamiresearch.com> Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.